Literature DB >> 27981412

Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication.

Alexander G Weil1, Anthony C Wang2, Harrison J Westwick1, George M Ibrahim3, Rojine T Ariani4, Louis Crevier1, Sebastien Perreault5, Tom Davidson6, Chi-Hong Tseng7, Aria Fallah8.   

Abstract

Medulloblastoma is the most common form of brain malignancy of childhood. The mainstay of epidemiological data regarding childhood medulloblastoma is derived from case series, hence population-based studies are warranted to improve the accuracy of survival estimates. To utilize a big-data approach to update survival estimates in a contemporary cohort of children with medulloblastoma. We performed a population-based retrospective observational cohort study utilizing the Surveillance, Epidemiology, and End Results Program database that captures all children, less than 20 years of age, between 1973 and 2012 in 18 geographical regions representing 28% of the US population. We included all participants with a presumed or histologically diagnosis of medulloblastoma. The main outcome of interest is survivors at 1, 5 and 10 years following diagnosis. A cohort of 1735 children with a median (interquartile range) age at diagnosis of 7 (4-11) years, with a diagnosis of medulloblastoma were identified. The incidence and prevalence of pediatric medulloblastoma has remained stable over the past 4 decades. There is a critical time point at 1990 when the overall survival has drastically improved. In the contemporary cohort (1990 onwards), the percentage of participants alive was 86, 70 and 63% at 1, 5 and 10 years, respectively. Multivariate Cox-Regression model demonstrated Radiation (HR 0.37; 95% CI 0.30-0.46, p < 0.001) and Surgery (HR 0.42; 95% CI 0.30-0.58, p < 0.001) independently predict survival. The probability of mortality from a neurological cause is <5% in patients who are alive 8 years following diagnosis. The SEER cohort analysis demonstrates significant improvements in pediatric medulloblastoma survival. In contrast to previous reports, the majority of patients survive in the modern era, and those alive 8 years following initial diagnosis are likely a long-term survivor. The importance of minimizing treatment-related toxicity is increasingly apparent given the likelihood of long-term survival.

Entities:  

Keywords:  Epidemiology; Medulloblastoma; Natural History; Population study; Prognosis; Survival; Time to event

Mesh:

Year:  2016        PMID: 27981412     DOI: 10.1007/s11060-016-2341-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

Authors:  André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Moving beyond evidence-based medicine: Incorporating patient values and preferences.

Authors:  Aria Fallah
Journal:  Epilepsy Behav       Date:  2015-11-06       Impact factor: 2.937

3.  SEER insights.

Authors:  John H Sampson; Shivanand P Lad; James E Herndon; Robert M Starke; Douglas Kondziolka
Journal:  J Neurosurg       Date:  2013-11-29       Impact factor: 5.115

4.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

Review 5.  Medulloblastoma: toward biologically based management.

Authors:  Ayman Samkari; Jason C White; Roger J Packer
Journal:  Semin Pediatr Neurol       Date:  2014-12-24       Impact factor: 1.636

6.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

7.  Medulloblastoma: a population-based study of 532 cases.

Authors:  R O Roberts; C F Lynch; M P Jones; M N Hart
Journal:  J Neuropathol Exp Neurol       Date:  1991-03       Impact factor: 3.685

8.  Limited utility despite accuracy of the national SEER dataset for the study of craniopharyngioma.

Authors:  Todd C Hankinson; Emma C Fields; Michelle R Torok; Brenda L Beaty; Michael H Handler; Nicholas K Foreman; Brent R O'neill; Arthur K Liu
Journal:  J Neurooncol       Date:  2012-08-23       Impact factor: 4.130

9.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.

Authors:  Dawn Elizabeth McNeil; Timothy R Coté; Limin Clegg; Lucy Balian Rorke
Journal:  Med Pediatr Oncol       Date:  2002-09

10.  Comparison of survival between the UK and US after surgery for most common pediatric CNS tumors.

Authors:  Ryan Koshy Mathew; Roddy O'Kane; Roger Parslow; Charles Stiller; Tom Kenny; Susan Picton; Paul Dominic Chumas
Journal:  Neuro Oncol       Date:  2014-05-05       Impact factor: 12.300

View more
  11 in total

1.  Tumor Location and Treatment Modality are Associated with Overall Survival in Adult Medulloblastoma.

Authors:  Anthony K Ma; Isaac Freedman; Jun Hui Lee; Danielle Miyagishima; Osama Ahmed; Jacky Yeung
Journal:  Cureus       Date:  2020-02-20

2.  Survival of infants ≤24 months of age with brain tumors: A population-based study using the SEER database.

Authors:  Claire Faltermeier; Timothy Chai; Sharjeel Syed; Nathan Lau; Lior Elkaim; George Ibrahim; Anthony Wang; Alexander Weil; Anne Bendel; Aria Fallah; Albert Tu
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

3.  Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma.

Authors:  Allison R Hanaford; Jesse Alt; Rana Rais; Sabrina Z Wang; Harpreet Kaur; Daniel L J Thorek; Charles G Eberhart; Barbara S Slusher; Allison M Martin; Eric H Raabe
Journal:  Transl Oncol       Date:  2019-07-21       Impact factor: 4.243

4.  Host Genome Variation is Associated with Neurocognitive Outcome in Survivors of Pediatric Medulloblastoma.

Authors:  Benjamin I Siegel; Tricia Z King; Manali Rupji; Bhakti Dwivedi; Alexis B Carter; Jeanne Kowalski; Tobey J MacDonald
Journal:  Transl Oncol       Date:  2019-05-09       Impact factor: 4.243

5.  A genome-wide association study on medulloblastoma.

Authors:  Anna M Dahlin; Carl Wibom; Ulrika Andersson; Jonas Bybjerg-Grauholm; Isabelle Deltour; David M Hougaard; Michael E Scheurer; Ching C Lau; Roberta McKean-Cowdin; Rebekah J Kennedy; Long T Hung; Janis Yee; Ashley S Margol; Jessica Barrington-Trimis; W James Gauderman; Maria Feychting; Joachim Schüz; Martin Röösli; Kristina Kjaerheim; Danuta Januszkiewicz-Lewandowska; Marta Fichna; Jerzy Nowak; Susan Searles Nielsen; Shahab Asgharzadeh; Lisa Mirabello; Ulf Hjalmars; Beatrice Melin
Journal:  J Neurooncol       Date:  2020-02-13       Impact factor: 4.130

6.  Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways.

Authors:  Khoa Pham; Allison R Hanaford; Brad A Poore; Micah J Maxwell; Heather Sweeney; Akhila Parthasarathy; Jesse Alt; Rana Rais; Barbara S Slusher; Charles G Eberhart; Eric H Raabe
Journal:  Cancers (Basel)       Date:  2022-03-03       Impact factor: 6.575

7.  Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016.

Authors:  Cristina Birlem Bleil; Jorge Wladimir Junqueira Bizzi; Andre Bedin; Francine Hehn de Oliveira; Ápio Cláudio Martins Antunes
Journal:  Surg Neurol Int       Date:  2019-06-25

Review 8.  Precision Medicine in Pediatric Neurooncology: A Review.

Authors:  Aaron Y Mochizuki; Isaura M Frost; Melina B Mastrodimos; Ashley S Plant; Anthony C Wang; Theodore B Moore; Robert M Prins; Paul S Weiss; Steven J Jonas
Journal:  ACS Chem Neurosci       Date:  2017-12-27       Impact factor: 4.418

9.  Medulloblastoma in a 6 Year Old Mixed Breed Dog: Surgical Debulking and Chemotherapy.

Authors:  Rachel Lampe; Miranda D Vieson; Devon Hague; Dana Connell; Kari Foss; Kim A Selting
Journal:  Front Vet Sci       Date:  2019-11-14

10.  Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study.

Authors:  Qilin Qin; Dezhi Huang; Yugang Jiang
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.